文献速递前列腺癌

活检初治患者的前列腺癌风险评估:鹿特丹前列腺癌风险计算器在多参数磁共振-经直肠超声融合靶向活检与系统经直肠超声活检中的应用

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

该研究在200例活检初治男性中比较了多参数磁共振(mpMRI)靶向活检(TBx)与系统经直肠超声活检(SBx)对前列腺癌(PCa)的检出率,并回顾性评估鹿特丹前列腺癌风险计算器(RPCRC)风险分层能否避免不必要的mpMRI和活检。结果显示TBx高级别PCa检出51例(26%),SBx检出63例(32%);基于RPCRC选择可避免37%的mpMRI,但遗漏4%的高级别PCa。

要点

  • TBx检出高级别PCa 51例(26%),SBx检出63例(32%)。
  • RPCRC建议阴性者中高级别PCa 4/73例(5%),阳性者中63/127例(50%)。
  • 基于RPCRC选择可避免73/200例(37%)mpMRI,遗漏2/51例(4%)高级别PCa。

核心结论

  • 在活检初治男性中,mpMRI联合TBx可检出高Gleason评分PCa并在低级别PCa中避免活检,但与SBx相比未能检出所有高级别PCa。
  • 使用RPCRC进行风险导向的患者选择可避免三分之一的mpMRI和SBx。

研究设计与样本

  • 两个中心连续纳入200例活检初治男性,均接受mpMRI、12针SBx,并在发现可疑病灶(PI-RADS v.2评分≥3)时行MRI-TRUS TBx。
  • 根据RPCRC活检建议进行回顾性分层,以确定可潜在避免的mpMRI和活检率及其与遗漏高级别PCa的关系。

主要发现

  • TBx检出高级别PCa 51例(26%)、低级别PCa 14例(7%)。
  • SBx检出高级别PCa 63例(32%)、低级别PCa 41例(21%)。
  • RPCRC建议阴性者中高级别PCa为4/73例(5%),建议阳性者为63/127例(50%)。
  • 基于RPCRC选择可避免73/200例(37%)mpMRI,遗漏2/51例(4%)高级别PCa。

临床怎么用

  • 作者认为,使用RPCRC进行个体化风险评估可避免三分之一的MRI扫描和系统前列腺活检。

局限性

  • 局限性包括RPCRC对高级别和低级别PCa的定义以及不同的mpMRI技术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The value of multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy (TBx) remains controversial for biopsy-naïve men when compared to transrectal ultrasound (TRUS)-guided systematic biopsy (SBx). Risk-based patient selection could help to selectively identify men with significant prostate cancer (PCa) and thus reduce unnecessary mpMRI and biopsies. OBJECTIVES: To compare PCa detection rates for mpMRI TBx with SBx and to determine the rate of potentially avoided mpMRI and biopsies through risk-based selection using the Rotterdam Prostate Cancer Risk Calculator (RPCRC). DESIGN, SETTING, AND PARTICIPANTS: Two-hundred consecutive biopsy-naïve men in two centres underwent mpMRI scanning, 12-core SBx, and subsequent MRI-TRUS TBx in the case of suspicious lesion(s) (Prostate Imaging-Reporting and Data System v.2 score ≥3). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We measured the detection rate for high-grade (Gleason score ≥ 3+4) PCa for TBx and SBx. We carried out a retrospective stratification according to RPCRC biopsy advice to determine the rate of mpMRI and biopsies that could potentially be avoided by RPCRC-based patient selection in relation to the rate of high-grade PCa missed. RESULTS AND LIMITATIONS: TBx yielded high-grade PCa in 51 men (26%) and low-grade PCa in 14 men (7%), while SBx yielded high-grade PCa in 63 men (32%) and low-grade PCa in 41 men (21%). Four out of 73 men (5%) with negative RPCRC advice and 63 out of 127 men (50%) with positive advice had high-grade PCa. Upfront RPCRC-based patient selection for mpMRI and TBx would have avoided 73 out of 200 (37%) mpMRI scans, missing two out of 51 (4%) high-grade PCas. Limitations include the RPCRC definition of high- and low-grade PCa and different mpMRI techniques. CONCLUSIONS: mpMRI with TBx detected PCa with high Gleason score and avoided biopsy in low-grade PCa, but failed to detect all high-grade PCa when compared to SBx among biopsy-naïve men. Risk-based patient selection using the RPCRC can avoid one-third of mpMRI scans and SBx in biopsy-naïve men. PATIENT SUMMARY: Men with a suspicion of prostate cancer are increasingly undergoing a magnetic resonance imaging (MRI) scan. Although promising, MRI-targeted biopsy is not accurate enough to safely replace systematic prostate biopsy for now. Individualised assessment of prostate cancer risk using the Rotterdam Prostate Cancer Risk Calculator could avoid one-third of MRI scans and systematic prostate biopsies.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mannaerts CK, Gayet M, Verbeek JF, et al. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy. Eur Urol Oncol. 2018. PMID: 31100233. doi:10.1016/j.euo.2018.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。